This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Thrombolysis  • Venous Thromboembolism  • Cardiovascular System  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

We thank Dr Theerman for his comments on the INR target in patients receiving oral anticoagulants. Although we agree that this treatment was associated with a high rate of bleeding in our patients, we do not agree with his suggestion of maintaining patients with acute VTE on a lower level of oral anticoagulation. Our study was designed to test a novel anticoagulant strategy (ie, long-term LMWH therapy), which has to be compared with a reference regimen. Warfarin therapy adjusted to obtain an INR of 2 to 3 is the current recommendation for treating VTE and is supported by a large body of literature.¹ In addition, strong and consistent data support that low INR values are associated with a high risk of recurrent thrombosis.² Finally, although patients with cancer are known to have an increased risk of bleeding when receiving anticoagulants, they also carry a higher risk of thromboembolic . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?